Supriya Lifescience delivers robust Q3 FY26 performance with 11% YoY revenue growth

The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25

Lupin Q3 FY26 consolidated PAT jumped 37.4% to Rs. 1,180.5 Cr

U.S. market achieved record quarterly sales of Rs. 3,113.2 crore ($350 million), a 54% YoY increase, accounting for 44% of global sales

Moderna signs five-year strategic mRNA vaccine pact with Mexico

Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health security

Aurobindo Pharma reports strong Q3 FY26 performance, boosted by Europe & ARV growth

Apollo Hospitals reports robust Q3 earnings; profit after tax humps to Rs. 3,835 million

Revenue from operations rose to Rs. 23,637 million for the three months ended December 31, 2025

Iambic taps AI to power multi-year drug discovery deal with Takeda

Veradermics completes enrollment in both Phase 3 male hair loss trials

The milestone means more than 1,000 men are now enrolled across both Phase 3 programs

India’s go-to diabetes test under scrutiny as new evidence flags major gaps

The paper highlights how conditions common across India—including anemia, inherited hemoglobin disorders, and glucose-6-phosphate dehydrogenase (G6PD) deficiency—can significantly distort HbA1c readings

Zydus Lifesciences reports strong Q3 & 9M FY26 growth

Revenue from operations surged 30% year-on-year to Rs. 68,645 million

Neuland Laboratories reports Rs 1,264.5 crore revenue for 9MFY26

The revenues this quarter are in line with the outlook we envisaged for the year